/
ACHV
$6.30+$0.13 (+2.02%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$646.8M
103M shares
52-week range
$2.37 – $7.11
83% from low
Sector
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Exchange
NASDAQ
CS
Change$-0.96
Achieve Life Sciences, Inc.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
www.achievelifesciences.com- Employees
- 28
- IPO / List date
- Oct 12, 1995
- HQ
- SEATTLE, WA
Held by traders on TradeandTell
No one on the platform currently holds ACHV.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 27,952 | $82.2K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2020-07-31 | 1-for-20reverse |
| 2018-05-24 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded ACHV yet.
